239 related articles for article (PubMed ID: 23435461)
1. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
Dreger P; Schnaiter A; Zenz T; Böttcher S; Rossi M; Paschka P; Bühler A; Dietrich S; Busch R; Ritgen M; Bunjes D; Zeis M; Stadler M; Uharek L; Scheid C; Hegenbart U; Hallek M; Kneba M; Schmitz N; Döhner H; Stilgenbauer S
Blood; 2013 Apr; 121(16):3284-8. PubMed ID: 23435461
[TBL] [Abstract][Full Text] [Related]
2. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
Schnaiter A; Paschka P; Rossi M; Zenz T; Bühler A; Winkler D; Cazzola M; Döhner K; Edelmann J; Mertens D; Kless S; Mack S; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2013 Aug; 122(7):1266-70. PubMed ID: 23821658
[TBL] [Abstract][Full Text] [Related]
3. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
4. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
[TBL] [Abstract][Full Text] [Related]
5. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
[TBL] [Abstract][Full Text] [Related]
6. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
[TBL] [Abstract][Full Text] [Related]
7. Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Baliakas P; Hadzidimitriou A; Sutton LA; Rossi D; Minga E; Villamor N; Larrayoz M; Kminkova J; Agathangelidis A; Davis Z; Tausch E; Stalika E; Kantorova B; Mansouri L; Scarfò L; Cortese D; Navrkalova V; Rose-Zerilli MJ; Smedby KE; Juliusson G; Anagnostopoulos A; Makris AM; Navarro A; Delgado J; Oscier D; Belessi C; Stilgenbauer S; Ghia P; Pospisilova S; Gaidano G; Campo E; Strefford JC; Stamatopoulos K; Rosenquist R;
Leukemia; 2015 Feb; 29(2):329-36. PubMed ID: 24943832
[TBL] [Abstract][Full Text] [Related]
8. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients.
Mansouri L; Grabowski P; Degerman S; Svenson U; Gunnarsson R; Cahill N; Smedby KE; Geisler C; Juliusson G; Roos G; Rosenquist R
Am J Hematol; 2013 Aug; 88(8):647-51. PubMed ID: 23620080
[TBL] [Abstract][Full Text] [Related]
9. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
Oscier DG; Rose-Zerilli MJ; Winkelmann N; Gonzalez de Castro D; Gomez B; Forster J; Parker H; Parker A; Gardiner A; Collins A; Else M; Cross NC; Catovsky D; Strefford JC
Blood; 2013 Jan; 121(3):468-75. PubMed ID: 23086750
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
11. The impact of SF3B1 mutations in CLL on the DNA-damage response.
Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
[TBL] [Abstract][Full Text] [Related]
12. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort.
Cortese D; Sutton LA; Cahill N; Smedby KE; Geisler C; Gunnarsson R; Juliusson G; Mansouri L; Rosenquist R
Leukemia; 2014 Mar; 28(3):710-3. PubMed ID: 24217197
[No Abstract] [Full Text] [Related]
13. Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
Sciumè M; Vincenti D; Reda G; Orofino N; Cassin R; Giannarelli D; Gaidano G; Rossi D; Cortelezzi A
Am J Hematol; 2015 Nov; 90(11):970-4. PubMed ID: 26201283
[TBL] [Abstract][Full Text] [Related]
14. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.
Rossi D; Rasi S; Spina V; Bruscaggin A; Monti S; Ciardullo C; Deambrogi C; Khiabanian H; Serra R; Bertoni F; Forconi F; Laurenti L; Marasca R; Dal-Bo M; Rossi FM; Bulian P; Nomdedeu J; Del Poeta G; Gattei V; Pasqualucci L; Rabadan R; Foà R; Dalla-Favera R; Gaidano G
Blood; 2013 Feb; 121(8):1403-12. PubMed ID: 23243274
[TBL] [Abstract][Full Text] [Related]
15. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
Guièze R; Robbe P; Clifford R; de Guibert S; Pereira B; Timbs A; Dilhuydy MS; Cabes M; Ysebaert L; Burns A; Nguyen-Khac F; Davi F; Véronèse L; Combes P; Le Garff-Tavernier M; Leblond V; Merle-Béral H; Alsolami R; Hamblin A; Mason J; Pettitt A; Hillmen P; Taylor J; Knight SJ; Tournilhac O; Schuh A
Blood; 2015 Oct; 126(18):2110-7. PubMed ID: 26316624
[TBL] [Abstract][Full Text] [Related]
16. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.
Rossi D; Rasi S; Spina V; Fangazio M; Monti S; Greco M; Ciardullo C; Famà R; Cresta S; Bruscaggin A; Laurenti L; Martini M; Musto P; Forconi F; Marasca R; Larocca LM; Foà R; Gaidano G
Br J Haematol; 2012 Aug; 158(3):426-9. PubMed ID: 22571487
[No Abstract] [Full Text] [Related]
17. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia.
Mansouri L; Cahill N; Gunnarsson R; Smedby KE; Tjönnfjord E; Hjalgrim H; Juliusson G; Geisler C; Rosenquist R
Leukemia; 2013 Feb; 27(2):512-4. PubMed ID: 23138133
[No Abstract] [Full Text] [Related]
18. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations.
Rigolin GM; del Giudice I; Formigaro L; Saccenti E; Martinelli S; Cavallari M; Lista E; Tammiso E; Volta E; Lupini L; Bassi C; Bardi A; Sofritti O; Daghia G; Cavazzini F; Marinelli M; Tavolaro S; Guarini A; Negrini M; Foà R; Cuneo A
Genes Chromosomes Cancer; 2015 Dec; 54(12):818-26. PubMed ID: 26355802
[TBL] [Abstract][Full Text] [Related]
19. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.
Jeromin S; Weissmann S; Haferlach C; Dicker F; Bayer K; Grossmann V; Alpermann T; Roller A; Kohlmann A; Haferlach T; Kern W; Schnittger S
Leukemia; 2014 Jan; 28(1):108-17. PubMed ID: 24113472
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
